BioVersys receives up to €8m from CARB-XSwiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections. more ➔
Researchers identify viral inflammation switchA team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion. more ➔
Rotavirus vaccines kill cancer cells Researchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines. more ➔
Polyphor presents AMR breakerSwiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics. more ➔
Zealand Pharma acquires EncycleZealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library. more ➔
Researchers target ferroptosis resistance of cancer cellsGerman researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer. more ➔
CHMP selects drugs for EU market approvalEMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting. more ➔
New risk factor for autism and epilepsy identifiedA molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders. more ➔
Healx Ltd raises $56m in Series B financingAI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases. more ➔
4SC expands domatinostat combo testingThe Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients. more ➔
